Innovent Biologics Closes Strategic Partnership with Takeda
Innovent Biologics has closed a global strategic partnership with Takeda, fulfilling their License, Option, and Collaboration Agreement, and Share Issuance Agreement. This led to the issuance of 6,913,834 shares, raising approximately HK$778 million. The partnership enhances Innovent's strategic positioning and financial resources for developing biologic medicines. The latest analyst rating for Innovent's stock (HK:1801) is a Hold with a HK$101.00 price target. Innovent Biologics focuses on innovative therapies in the pharmaceutical industry.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Innovent Biologics ( (HK:1801) ) has issued an announcement.
Innovent Biologics, Inc. has successfully closed a global strategic partnership with Takeda, fulfilling all conditions of their License, Option, and Collaboration Agreement, as well as the Share Issuance Agreement. This resulted in the issuance of 6,913,834 shares, raising approximately HK$778 million in gross proceeds. The transaction enhances Innovent’s strategic positioning and financial resources, allowing further development in their biologic medicines portfolio.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$101.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a biotechnology company incorporated in the Cayman Islands, focusing on the development and commercialization of biologic medicines. The company operates in the pharmaceutical industry, with a market focus on innovative therapies.
Average Trading Volume: 16,162,592
Technical Sentiment Signal: Buy
Current Market Cap: HK$160.8B
